Precision BioSciences has grand regulatory ambitions for its lead program: first allogeneic CAR-T therapy on the market.
En route to meeting with the FDA later this year on potential registration strategy, the North Carolina biotech is out with new interim Phase I/IIa clinical data on its prized possession, dubbed PBCAR0191....
